Company: IOBT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058699
Chunk: 29

Company: IO Biotech, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 29
---
,000 |     |        | 50,000 |     |        | 417,476 |     |                | 233,280 |     |              |      — |     |           |   920,756 |
| Amy Sullivan, M.B.A.,          |     | 2024 |     |            | 439,875 |     |        |      — |     |        | 347,704 |     |                | 198,000 |     |              | 12,833 |     |           |   998,412 |
| Chief Financial Officer        |     | 2023 |     |            |       — |     |        |      — |     |        |       — |     |                |       — |     |              |      — |     |           |         — |

(1) Unless indicated otherwise, amounts reported in this table for Dr. Zocca (i) for 2023 and 2024, are the U.S. dollar values of compensation paid in DKK with a USD/DKK exchange rate of 6.9738 on March 1, 2023. (2) Amount reported for Dr. Ahmad for 2023 represents a cash sign-on bonus paid in connection with the commencement of his employment. (3) Amounts reported for 2024 represent the grant date fair value of options granted in 2024 to each of the named executive officers, calculated in accordance with ASC 718. See Note 12 to the Audited Financial Statements included in our Form 10-K for the fiscal year ended December 31, 2024 for a discussion of the relevant assumptions used in calculating these amounts. (4) Amounts reported for 2024 in this column for each named executive officer represents payouts under the Company’s annual cash bonus program based on achievement against corporate and individual goals, as described above. (5) Amounts reported for Dr. Zocca, Dr. Ahmad and Ms. Sullivan represent retirement plan contributions, as discussed further below in “Pension Plan.” (6) Ms. Sullivan was not a named executive officer in 2023.

<div align='center'>22</div>

Outst anding Equity Awards at 2024 Fiscal Year-End The following table presents information regarding the outstanding warrants and stock options held by each of the named executive officers as of December 31, 2024. None of the named executive officers held any outstanding restricted stock or other equity awards as of that date.

|